The content on this site is intended for healthcare professionals only
At a press conference at SABCS 2014, Dr Prudence Francis presents data on adding ovarian suppression to tamoxifen reduced recurrence for some women with premenopausal breast cancer.
A 35 percent decrease in risk of breast cancer recurrence was observed for premenopausal women who received chemotherapy for early-stage, hormone receptor-positive breast cancer and were assigned exemestane with ovarian suppression compared with those assigned tamoxifen.
Read the news story or watch the interview for more.
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
OncoAlert round up July 28th to August 3rd, 2023
PHERGain trial ID's early breast cancer cases that benefit from dual HER2 blockade without chemo
ASCO 2023: Breast cancer research highlights
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
The role of lymph nodes in stage 3 lung cancer
Loco-regional management after neoadjuvant chemotherapy
